Grit Biotechnology
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $60M
Overview
A cell therapy biotech engineering next-generation CAR-T cells to effectively treat solid tumors.
OncologyCell Therapy
Technology Platform
A platform for engineering multi-functional CAR-T cells with enhanced abilities to persist and attack within the immunosuppressive solid tumor microenvironment.
Funding History
1Total raised:$60M
Series B$60M
Opportunities
Being first to demonstrate durable efficacy in a major solid tumor indication with a cell therapy would be a monumental breakthrough with vast commercial potential.
Risk Factors
Faces significant biological complexity, potential for severe toxicity, and intense competition in the solid tumor cell therapy arena.
Competitive Landscape
Enters a highly competitive race to develop effective CAR-T therapies for solid tumors, competing with dozens of well-funded biotechs and academic centers.